Alle Fälle anzeigen
ACT 831/2025
—·EP2196231: System for ambulatory drug infusion comprising a filling apparatus for flexible containers
- Verfahrensdetails
- Status—VerfahrensartKostenfestsetzungKategorieKostenfestsetzungen
- Parteien
- KlägerVertreter: Christof Augenstein (Kather Augenstein); Katharina Brandt (Kather Augenstein); Robert Knaps (Kather Augenstein); Thomas Kronberger (Grünecker Patent- und Rechtsanwälte PartGmbH)BeklagteVertreter: Charlotte Garnitsch (Taylor Wessing); Wim Maas (Taylor Wessing); Alexander Rubusch (Taylor Wessing)
- Division
- Paris CD
- Richter
- Paolo Catallozzi · Presiding judge and judge-rapporteur
- Tatyana Zhilova · Legally qualified judge
- Giorgio Checcacci · Technically qualified judge
- Technology
- Pharmaceutical & Medical
- Sprache
- —
- Erste Entscheidung
- 29. Apr. 2025
Entscheidungen
- 2025-04-29Nur KostenKostenApplication For Costs
The Central Division Paris issued a costs order in connection with the revocation action UPC_CFI_454/2023, requiring Tandem Diabetes to pay Roche Diabetes Care's representation and litigation costs. The Court rejected Tandem Diabetes's request to stay the costs proceedings pending the appeal against the decision on the merits.
Rechtsfragen:Costs decisionStay of costs proceedingsPending appeal against merits decisionReimbursable representation costs ceilingArt. 69 UPCA - 2025-04-29Nur KostenKostenApplication For Costs
The Paris Central Division issued a cost decision ordering Tandem Diabetes Care to pay Roche Diabetes Care's legal costs of EUR 112,000 plus travel expenses and court fees totalling approximately EUR 119,623, following Roche's success in the underlying revocation action.
Rechtsfragen:Cost decision (Art. 69 UPCA)Stay of cost proceedings pending appealReimbursement of travel expenses for in-house representatives
Dokumente
- 14AF9E89CF5211C49BDEB00516141CAA_en.pdf2025-04-29EN
- 381B3A937B73E93E29D4A3AEDE26207D_en.pdf2025-04-29EN